BWBrilliant Citra Wirashada

Brilliant Citra Wirashada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brilliant Citra Wirashada has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A global bibliometric analysis of the scientifc landscape and collaborative networks in prostate cancer and bioinformatics research

    by Lalu Muhammad Irham, Wirawan Adikusuma, Sabiah Khairi, Syarifatul Mufidah, Rahmat Dani Satria, Eko Mugiyanto, Indra Jaya, Darmawi Darmawi, Petrina Theda Philothra, Desti Rahmawati, et al.

    Background . Prostate cancer is a leading malignancy among men worldwide, presenting signifcant public health challenges due to its complex biology and diverse clinical outcomes. Recent advances in bioinformatics have greatly infuenced cancer research by enabling the integration of multiple disciplines and improving the analysis of biological data. Objective . To present a comprehensive bibliometric analysis summarizing global research trends in prostate cancer and bioinformatics from 1998 to 2025. Material and Methods . A bibliometric study was conducted analyzing 3,426 articles sourced from 961 publications. Data on research output, collaboration patterns, citation impact, and thematic clusters were extracted and analyzed. Results . The feld exhibited a robust annual growth rate of 18.42 %, with an average document age of 5.65 years and 26.34 citations per article, indicating high scientifc impact. Collaborative research is prevalent, with 13,598 authors averaging 7.21 co-authors per publication and over 21 % of research produced via international partnerships. Publication formats included journal articles, reviews, and conference papers. Keyword cooccurrence analysis revealed fve main thematic clusters: computational and omics methodologies; tumor biology and immunology; molecular mechanisms and cancer progression; biomarkers and gene regulation; and interdisciplinary cancer research. Publication patterns indicated steady output before 2013 followed by a marked surge peaking near 500 articles in 2023, driven by advancements in genomics, big data analytics, and precision oncology. Citation data highlighted the United States and China as leading contributors, with China leading in publication count through predominantly domestic research, while the United States featured more international collaborations. Other signifcant contributors included Australia, Germany, Canada, and several European and Asian countries. Conclusion . Research at the intersection of prostate cancer and bioinformatics is rapidly expanding, highly collaborative, and globally distributed. The multidisciplinary and integrative nature of this feld continues to advance understanding, diagnosis, and treatment of prostate cancer through cutting-edge bioinformatics approaches.

  • Open Access

    Gene variants that may cause adverse drug reactions in non-Hodgkin’s lymphoma therapy: a genomic and bioinformatics approach

    by R. Gustinanda, L. M. Irham, W. Supadmi, D. P. Amukti, W. Adikusuma, R. Chong, R. El Khair, R. D. Satria, B. C. Wirsahada

    Introduction. Chemotherapy remains a cornerstone treatment for most non-Hodgkin lymphoma (NHL) patients, yet it is frequently associated with significant adverse effects that compromise their quality of life. Emerging evidence highlights that genetic factors, particularly single nucleotide polymorphisms (SNPs), play a critical role in determining individual variability in treatment responses and susceptibility to drug-related complications.Aim of this study: to identify SNPs associated with chemotherapy-induced adverse events in NHL through advanced bioinformatics approaches, enabling personalized therapeutic strategies to mitigate risks.Material abd Methods. This study leveraged the PharmGKB database to identify SNPs associated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. SNPs meeting inclusion criteria (Level of Evidence 1A-3, pResults. This study identified 11 SNPs that may be important for hematological toxicity, liver damage, and nausea risk. These genes are SLC22A16, GSTP1, NAT2, ATM, ABCB1, CYP2B6, XRCC1, ERCC1, MUTYH PIK3R2, and PNPLA3. In terms of priority and risk, the most significant variants were rs738409 (PNPLA3), rs12210538 (SLC22A16), rs2229109 (ABCB1), and rs56022120 (PIK3R2). The distribution of SNP alleles is more common in European populations than in Asians or Africans.Conclusion. For the first time, we found SNPs that indicate an increase in drug side effects. These SNPs rs738409, rs12210538, rs2229109 and rs56022120 increase the severity of NHL patients during chemotherapy. In order to ensure that these biomarkers can be used in clinical practice and to support the creation of precision medicine strategies, additional clinical validation is needed.